Literature DB >> 30159892

Rescue therapies for seizure emergencies: New modes of administration.

Patricia D Maglalang1, Davin Rautiola2, Ronald A Siegel2, Jared M Fine3, Leah R Hanson3, Lisa D Coles1,4, James C Cloyd1,4.   

Abstract

A subgroup of patients with drug-resistant epilepsy have seizure clusters, which are a part of the continuum of seizure emergencies that includes prolonged episodes and status epilepticus. When the patient or caregiver can identify the beginning of a cluster, the condition is amenable to certain treatments, an approach known as rescue therapy. Intravenous drug administration offers the fastest onset of action, but this route is usually not an option because most seizure clusters occur outside of a medical facility. Alternate routes of administration have been used or are proposed including rectal, buccal, intrapulmonary, subcutaneous, intramuscular, and intranasal. The objective of this narrative review is to describe the (1) anatomical, physiologic, and drug physicochemical properties that need to be considered when developing therapies for seizure emergencies and (2) products currently in development. New therapies must consider parameters of Fick's law such as absorptive surface area, blood flow, membrane thickness, and lipid solubility, because these factors affect both rate and extend of absorption. For example, the lung has a 50 000-fold greater absorptive surface area than that associated with a subcutaneous injection. Lipid solubility is a physicochemical property that influences the absorption rate of small molecule drugs. Among drugs currently used or under development for rescue therapy, allopregnanolone has the greatest lipid solubility at physiologic pH, followed by propofol, midazolam, diazepam, lorazepam, alprazolam, and brivaracetam. However, greater lipid solubility correlates with lower water solubility, complicating formulation of rescue therapies. One approach to overcoming poor aqueous solubility involves the use of a water-soluble prodrug coadministered with a converting enzyme, which is being explored for the intranasal delivery of diazepam. With advances in seizure prediction technology and the development of drug delivery systems that provide rapid onset of effect, rescue therapies may prevent the occurrence of seizures, thus greatly improving the management of epilepsy. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  acute repetitive seizures; benzodiazepines; intramuscular; intranasal; intrapulmonary; rescue therapy; seizure clusters; subcutaneous

Mesh:

Substances:

Year:  2018        PMID: 30159892     DOI: 10.1111/epi.14479

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Editorial: Intranasal Delivery of Central Nervous System Active Drugs: Opportunities and Challenges.

Authors:  Márcio Rodrigues; Javed Ali; Gilberto Alves
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

2.  Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.

Authors:  James W Wheless; Ian Miller; R Edward Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2021-08-21       Impact factor: 6.740

3.  Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats.

Authors:  Davin Rautiola; Patricia D Maglalang; Narsihmulu Cheryala; Kathryn M Nelson; Gunda I Georg; Jared M Fine; Aleta L Svitak; Katherine A Faltesek; Leah R Hanson; Usha Mishra; Lisa D Coles; James C Cloyd; Ronald A Siegel
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

4.  Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial.

Authors:  Abhishek G Sathe; Holly Tillman; Lisa D Coles; Jordan J Elm; Robert Silbergleit; James Chamberlain; Jaideep Kapur; Hannah R Cock; Nathan B Fountain; Shlomo Shinnar; Daniel H Lowenstein; Robin A Conwit; Thomas P Bleck; James C Cloyd
Journal:  Acad Emerg Med       Date:  2019-07-18       Impact factor: 5.221

Review 5.  The unmet need for rapid epileptic seizure termination (REST).

Authors:  Aviva Asnis-Alibozek; Kamil Detyniecki
Journal:  Epilepsy Behav Rep       Date:  2020-11-25

6.  Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial.

Authors:  Abhishek G Sathe; Ellen Underwood; Lisa D Coles; Jordan J Elm; Robert Silbergleit; James M Chamberlain; Jaideep Kapur; Hannah R Cock; Nathan B Fountain; Shlomo Shinnar; Daniel H Lowenstein; Eric S Rosenthal; Robin A Conwit; Thomas P Bleck; James C Cloyd
Journal:  Epilepsia       Date:  2021-02-10       Impact factor: 5.864

Review 7.  Rescue therapies for seizure emergencies: current and future landscape.

Authors:  Debopam Samanta
Journal:  Neurol Sci       Date:  2021-07-16       Impact factor: 3.830

8.  Efficacy, Tolerability, and Safety of Concentrated Intranasal Midazolam Spray as Emergency Medication in Epilepsy Patients During Video-EEG Monitoring.

Authors:  Anemone von Blomberg; Lara Kay; Susanne Knake; Sven Fuest; Johann Philipp Zöllner; Philipp S Reif; Eva Herrmann; Ümniye Balaban; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2020-05       Impact factor: 5.749

9.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

10.  Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.

Authors:  Ian Miller; James W Wheless; Robert E Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia Open       Date:  2021-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.